Generic filters
Filter by content type
Taxonomy terms

VTYX – Ventyx Biosciences Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 41.14

Low: 30

High: 63

Total Analysts: 6

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with significant unmet need. Its pipeline includes VTX958, VTX002, and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). Its lead product candidate, VTX958, is an oral, selective allosteric tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, Crohns disease, psoriatic arthritis and lupus. VTX958 is designed to selectively inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for the treatment of ulcerative colitis (UC). Its lead NLRP3 inhibitor product candidate, VTX2735, is designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan